Association of Hypometilating Agents (HMA) plus Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine-MedSci.cn

Association of Hypometilating Agents (HMA) plus Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Latagliata, R; Cambò, B; Piccioni, AL; Federico, V; Cristiano, G; Lugli, E; Rizzo, L; Santopietro, M; Mazzone, C; Bonifacio, M; Palmieri, R; Poloni, A; Biagi, A; Binotto, G; Delfina, M; Annunziata, M; Molteni, A; Piedimonte, M; Carmosino, I; Di Veroli, A; Niscola, P; Riva, M; Capodanno, I; Curti, A; Di Rienzo, N; Fenu, S; Crugnola, M

BLOOD, 2023; 142 ():

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Association of Hypometilating Agents (HMA) plus Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

科室

工具

服务